Literature DB >> 237499

Plasma albumin concentration and diphenylhydantoin binding in man.

R J Porter, R B Layzer.   

Abstract

The plasma protein binding of diphenylhydantoin sodium was determined in 26 patients who had been taking diphenylhydantoin regularly for more than two weeks. The free (unbound) diphenylhydantoin level was found to vary from 5.8% to 12.6% of the total drug concentration. This range of variation may be clinically important, if it can be established that the binding of diphenylhydantoin to plasma proteins limits entry of the drug into the brain. The binding of diphenylhydantoin was directly proportional to the plasma albumin concentration, which thus appeared to be the most important determinant of diphenylhydantoin binding. Diphenylhydantoin binding was independent of the plasma concentration of the drug in the usual therapeutic range. In vitro studies showed little effect by phenobarbital sodium or penicillin G; therapeutic levels of acetylsalicylic acid, however, increased free diphenylhydantoin by nearly 50%.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237499     DOI: 10.1001/archneur.1975.00490470042005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

1.  Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.

Authors:  G J Johnson; C J Kilpatrick; R W Bury; R O Fullinfaw; R F Moulds
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

2.  Ultrafiltration vs equilibrium dialysis for determination of free fraction.

Authors:  W F Bowers; S Fulton; J Thompson
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 3.  Plasma protein binding of drugs in pregnancy.

Authors:  E Perucca; A Crema
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

4.  Plasma protein binding of phenytoin in the aged: in vivo studies.

Authors:  M Patterson; R Heazelwood; B Smithurst; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

5.  Plasma protein binding of phenytoin in 100 epileptic patients.

Authors:  G M Peterson; S McLean; S Aldous; R J Von Witt; K S Millingen
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.

Authors:  N Barth; G Alván; O Borgå; F Sjöqvist
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

8.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

9.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.